Next generation transpososomes
AssigneesVanderbilt University, The United States of America, as represented by the Secretary, Department of Health and Human Servic
InventorsMatthew H. Wilson, Frederick Dyda, Alison B. Hickman, Wentian Lou
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a modified transposase, comprising a core piggy Bac transposase having one or more modifications making it capable of excising and integrating a piggy Bac transposon in LE/LE configuration leading to hyperactivity. Also disclosed is a modified piggy Bac transposase capable of excising but not integrating a piggy Bac transposon in LE/LE configuration. Also disclosed herein is a modification of the mammalian Myotis lucifugus DNA transposon involving modification both its transposase and transposon LE and RE ends by truncations leading to hyperactivity.
Claims23
A modified transposase, comprising a core piggyBac transposase lacking one or more of the N-terminal 74 amino acids, having a duplication of the C-terminal 53 amino acids, or a combination thereof.
A modified transposase, comprising a core of piggy Bat transposase with the following point mutations:
- S8 to A, S24 to A, S32 to A, S37 to A and having a duplication of the C-terminal 81 amino acids,
A modified piggyBat transposon that contains only the first 88 nucleotides of the transposon left end (LE) and only the first 100 nucleotides of the transposon right end (RE).
Dependencies are inferred from the claim text.